ATS 2018 International Conference

Rationale and Design of TRACE: A Double-Blind, Placebo-Controlled Phase 4 Study in Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Physical Activity, Patient-Reported Symptoms and Their Impact, in Daily Life [Board No. P171]

Location: Board no. P171

Session Type: Thematic Poster Session

Tuesday

May

11:15 AM

1:00 PM

Speaker(s)/Author(s)

Robert P. Frantz

MD
Mayo Clinic

Hall Skaara

MD
Pulmonary Hypertension Association (PHA) Europe

Ioana R. Preston

MD
Tufts Med Center;Tufts Medical Center

Stephan Rosenkranz

MD
Cologne University Heart Center;Department of Cardiology;Herzzentrum der Universitaet zu Koeln;University of Cologne

Thomas Pfister

MD
Actelion Pharmaceuticals Ltd

Luke S. Howard

PhD
Hammersmith Hospital;Hammersmith Hospital, Imperial College London, National Pulmonary Hypertension Service

Anna Hemnes

MD
Vanderbilt Univ;Vanderbilt University;Vanderbilt University Medical Center

Marc Humbert

MD, PhD
Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud;Assistance-Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Su

View Abstract

Rationale and Design of TRACE: A Double-Blind, Placebo-Controlled Phase 4 Study in Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Physical Activity, Patient-Reported Symptoms and Their Impact, in Daily Life

Parent Sessions

C69 - USE YOUR ILLUSION: NOVEL THERAPEUTIC APPROACHES IN PULMONARY HYPERTENSION...
05-22-2018 9:15 AM - 4:15 PM

Event